<DOC>
	<DOCNO>NCT00027742</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Interferon alfa may interfere growth cancer cell . Combining chemotherapy interferon alfa may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine temozolomide interferon alfa treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Temozolomide Interferon Alfa Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient advance melanoma treat temozolomide pegylated interferon alfa . - Determine toxicity profile regimen patient . - Determine duration disease response overall survival patient treat regimen . OUTLINE : Patients stratify accord CNS metastasis ( yes v ) . Patients receive oral temozolomide daily week 1-6 pegylated interferon alfa subcutaneously weekly week 1-8 . Courses repeat every 8 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 23-61 patient ( 12-35 without CNS metastases 11-26 CNS metastasis ) accrue study within 18 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma Unresectable stage III stage IV disease Ocular , mucosal , cutaneous melanoma Measurable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT/SGPT great 3 time ULN Alkaline phosphatase great 3 time ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No history severe cardiovascular disease No myocardial infarction within past 6 month No unstable angina No New York Heart Association class III IV heart disease ( congestive heart failure ) No ventricular tachyarrhythmias Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No AIDSrelated illness No frequent vomit medical condition would preclude oral medication intake ( e.g. , partial bowel obstruction ) No serious infection require IV antibiotic No psychiatric disorder require ongoing therapy medication No nonmalignant illness medical condition would preclude study No active malignancy within past 2 year except nonmelanoma skin cancer , carcinoma situ cervix , T1a b prostate cancer detect initially transurethral resection prostate ( TURP ) ( comprise less 5 % resected tissue ) PSA level normal since TURP PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy immunotherapy recover No concurrent immunotherapy Chemotherapy : No prior dacarbazine No prior temozolomide No concurrent chemotherapy Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : At least 3 week since prior radiotherapy , interstitial brachytherapy , radiosurgery At least 3 week since prior radiotherapy brain brain metastasis Prior radiotherapy indicator lesion allow evidence disease progression Recovered prior radiotherapy No concurrent radiotherapy Surgery : At least 2 week since prior surgical procedure require general anesthesia recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>iris melanoma</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>